A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Next Previous
Trial Profile

A Phase II Study of Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Mar 2016

At a glance

  • Drugs Ponatinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Mar 2016 Time frame of the primary end point changed from 24-36 months to 2-4 months, according to ClinicalTrials.gov record.
    • 16 Mar 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top